Drug intelligence / Profile preview

Nanofen Gel

Development stage: Unknown
Lead developer: Achilles Healthcare
Modality: Small Molecules
Administration: Topical

Overview

**Nanofen Gel** is a marketed topical fixed-dose analgesic and anti-inflammatory combination developed and manufactured by Achilles Healthcare. It contains diclofenac diethylamine, linseed oil, methyl salicylate, and menthol in a gel formulation for localized musculoskeletal pain, swelling, and inflammation. Diclofenac inhibits cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation and pain, while methyl salicylate and menthol provide topical counterirritant and analgesic effects. ([achilleshealthcare.com](https://www.achilleshealthcare.com/products.html))

Brand names: Nanofen Gel
Other names: diclofenac diethylamine + linseed oil + menthol + methyl salicylate

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Nanofen Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanofen Gel.

Explore the full profile